
# ANEURYSM REGRESSION WITH THE **GORE® EXCLUDER®** AAA ENDOPROSTHESIS

Recent studies<sup>1,2</sup> suggest there is an independent association between aneurysm sac behavior and patient mortality after EVAR. Deery et al., states that sac regression predicted a decrease in late mortality and O'Donnell et al., states that any failure of the sac to regress is associated with higher long-term mortality, independent of reinterventions or endoleaks.

Data from the Global Registry for Endovascular Aortic Treatment (GREAT) shows that AAA's treated with the GORE<sup>®</sup> EXCLUDER<sup>®</sup> AAA Endoprosthesis compare favorably to one-year data from the Vascular Quality Initiative (VQI). In the VQI analysis of 14,817 patients done by O'Donnell et al., 40% of AAA sacs regressed, 35% remained stable and 25% expanded.<sup>2</sup>



Change in aneurysm sac diameter (mm) in patients treated with the GORE® EXCLUDER® AAA Device

The change in aneurysm sac diameter (mm) from the baseline (one month) measurement is shown at each year follow-up (FU) window, up to the five year FU window.

GORE

Together, improving life

No change (< 5 mm) from baseline Increase  $\geq$  5 mm from baseline

# Durable Outcomes. Proven Performance.

The GORE® EXCLUDER® AAA Device is associated with low reintervention rates, a 71.1% freedom from all-cause mortality\* through 5 years and has been proven through clinical trials, registries and site reported use, to be a safe, effective and durable solution, earning the trust of physicians worldwide.

### GORE® EXCLUDER® AAA Device data from GREAT<sup>+</sup>

Length of follow-up (through)	5 years
Number of patients possible	3,274
Freedom from aneurysm-related mortality	98.8%
Freedom from all reintervention	92.0%
Freedom from device related reintervention	94.7%
Conversion to open repair	0.8%
Aneurysm-related rupture	0.3%
Migration <sup>+</sup>	0.0%
Type la endoleak	0.9%
Type lb endoleak	0.7%
Type III endoleak	0.2%
Limb occlusion	0.7%
Renal complication <sup>§</sup>	0.4%

### Contact your local Field Sales Associate for more information

\* Kaplan Meier estimate of Freedom from Mortality of 71.1% with a 95% Cl of 68.5–73.5%. Analysis is a point estimate through 5 years.

† To calculate the overall event rates from procedure through end of study period, all subjects who could have had events, regardless of length of follow-up, were included. For outcome data, GREAT only collects site reported serious adverse events. Therefore, all reported endoleaks are defined as serious and require reintervention.

<sup>‡</sup> One peri-procedural migration reported. Zero migrations reported during follow-up through 5 years.

§ Inclusion for renal complication rate: Subjects with renal complication were identified with MedDRA code. Of those identified with MedDRA code as having a renal complication, only those who showed the SAE occurring within 75 days of the procedure AND were reported by the site/physician as being related to the device or procedure were included in the renal complication rate.

 Deery SE, Ergul EA, Schermerhorn ML, Siracuse JJ, Schanzer A, Goodney PP, et al. Aneurysm sac expansion is independently associated with late mortality in patients treated with endovascular aneurysm repair. Journal of Vascular Surgery 2018;67:157-64.

2. O'Donnell TFX, Deery SE, Boitano LT, *et al*. Aneurysm sac failure to regress after endovascular aneurysm repair is associated with lower long-term survival. *Journal of Vascular Surgery* 2019;69:414-422.

#### Consult Instructions for Use eifu.goremedical.com

Refer to *Instructions for Use* at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available.  $R_{x \text{ only}}$ 

Products listed may not be available in all markets.

GORE, *Together, improving life*, EXCLUDER and designs are trademarks of W. L. Gore & Associates. © 2020 W. L. Gore & Associates, Inc. AZ1395-EN2 AUGUST 2020

W. L. Gore & Associates, Inc. goremedical.com

